Page last updated: 2024-08-23
paclitaxel and ps1145
paclitaxel has been researched along with ps1145 in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Cui, Y; Hong, Y; Li, Y; Wu, Y; Yang, G; Yang, L; Zhou, J; Zhou, Y | 1 |
Other Studies
1 other study(ies) available for paclitaxel and ps1145
| Article | Year |
|---|---|
Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cisplatin; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Lung Neoplasms; Mice, Inbred BALB C; Mutation; NF-kappa B; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Transcription Factor RelA; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |